SELECT MDS-1

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 3
Enrollment
550 patients (estimated)
Sponsors
Syros Pharmaceuticals
Tags
Antimetabolites, Hypomethylating Agents (HMA), Retinoic Acid Receptor Alpha (RAR-α) / NR1B1, Placebo, Randomization
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1367
NCT Identifier
NCT04797780

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.